Ipamorelin vs CJC-1295: Two Receptors, When to Choose One Over the Other

Looking to stack them instead? This post compares the two head-to-head for people choosing between them. If you're evaluating the combined protocol (which is what most people actually run), start with the Ipamorelin + CJC-1295 Stack Guide, it covers dosing, pinning, and the combined-evidence case.

Here's the punchline up front: ipa and CJC-1295 aren't really alternatives. They hit completely different receptors, and that's exactly why almost everyone who tries one ends up running both. The "vs" framing is misleading. What this post actually answers is: what does each do alone, when does picking one make sense, and what's the deal with DAC vs no-DAC, the part that trips up most first-timers.

Key Takeaways

• —Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist, it triggers a GH pulse via the ghrelin pathway without touching cortisol or prolactin (Raun et al., European Journal of Endocrinology, 1998).
• —CJC-1295 is a GHRH analog, it binds GHRH receptors and stimulates the somatotropic axis through an orthogonal pathway (Teichman et al., JCEM, 2006).
• —Stacking both produces additive-to-synergistic GH pulses in healthy volunteers; neither replaces the other.
• —CJC-1295 comes in two flavors: DAC (drug affinity complex, 6–8 day half-life) and no-DAC / Mod GRF 1-29 (~30 min half-life). Not interchangeable.
• —Ipa runs 200–300 mcg ED or BID; CJC-1295 DAC is once-weekly; no-DAC CJC-1295 mirrors ipa, daily, usually pre-bed.

The Core Distinction: Two Receptors, One Outcome

GH release from the pituitary has two stimulatory inputs and one inhibitor. GHRH from the hypothalamus binds the GHRH receptor on pituitary somatotrophs and pushes GH out. Ghrelin, the hunger peptide from the stomach, binds GHSR-1a on those same somatotrophs through a parallel pathway. Somatostatin shuts both down.

Both stimulatory pathways converge on GH release but they run through different receptors and different intracellular cascades. That's the whole mechanistic case for stacking them: amplify both inputs and you get a bigger GH pulse than either alone. The human data backs this up. In healthy male volunteers, co-administering a GHRH analog with a ghrelin-receptor agonist produced GH peaks ~3–5x higher than either compound alone (Hataya et al., JCEM, 2001).

What Ipamorelin Does Alone

Ipamorelin is a pentapeptide (H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂) built as a selective GHSR-1a agonist. The selectivity is the whole point. Earlier ghrelin-mimetics like GHRP-2 and GHRP-6 also kicked up cortisol and prolactin because they hit related receptors. Ipa was engineered to bind GHSR-1a with high affinity while skipping cortisol, ACTH, and prolactin (Raun et al., 1998).

Clean selectivity matters because the whole reason you'd run a ghrelin-mimetic for GH is to get the pulse without the stress-axis baggage. The trade-off: ipa produces a smaller GH pulse per dose than GHRP-2, but no cortisol spike, no ACTH bump, no extra hunger.

Half-life: ~2 hours subq. Typical research dose: 200–300 mcg subq, 1–3x daily. Common pattern: pre-bed pin to ride the natural overnight GH pulse.

What CJC-1295 Does Alone

CJC-1295 is a 30-amino-acid GHRH analog (residues 1–29 of endogenous GHRH, with four substitutions to resist enzymatic degradation). It binds the GHRH receptor on pituitary somatotrophs and pulls GH out.

The thing that matters most: there are two versions with completely different pharmacokinetics.

CJC-1295 DAC (drug affinity complex) has a maleimide group that covalently locks onto serum albumin after injection. That stretches the half-life out to ~6–8 days (Teichman et al., JCEM, 2006). In clinical trials, weekly dosing at 60–250 mcg/kg produced sustained GHRH-receptor activation and elevated IGF-1 across the entire inter-dose window.

CJC-1295 no-DAC, also sold as Mod GRF 1-29, has the same amino acid substitutions but skips the albumin-binding group. Half-life crashes to ~30 minutes. This version mirrors ipa's rhythm: daily pulsatile dosing, not weekly.

The two versions aren't clinically interchangeable. DAC produces continuous GHRH signalling; no-DAC produces pulsatile GHRH signalling. Different physiological effects. The "CJC-1295 + ipa" protocol you see in most peptide references specifically uses no-DAC. Pairing DAC with ipa is a different protocol with different trade-offs.

Head-to-Head Comparison

Ipa alone gives you a clean ghrelin-pathway GH pulse with no stress-axis activation. Effect size is modest, side effect profile is clean.

CJC-1295 no-DAC alone gives you a clean GHRH-pathway GH pulse with preserved pulsatility. Almost nobody runs it solo because pairing with ipa is mechanistically better.

CJC-1295 DAC alone gives you sustained GHRH signalling and elevated IGF-1. Pulsatility is gone. That matters because chronic GHRH-receptor activation eventually desensitises the pituitary, while pulsatile signalling keeps the response intact.

Why the Combination Dominates Protocols

Ipa + CJC-1295 (no-DAC) is one of the most-run pairings in peptide protocols, and the mechanistic case is clean:

1. —Independent receptors. Ghrelin-receptor activation and GHRH-receptor activation converge on GH release but come from different intracellular cascades. Stacking both inputs adds rather than competes.
2. —Preserved pulsatility. Both peptides clear fast, so dosing doesn't desensitise the pituitary. Multiple pulses per day stay effective.
3. —No stress-axis hit. Neither one bumps cortisol, ACTH, or prolactin. Pure GH-axis stimulus.
4. —Sum bigger than parts. Published GHRH + ghrelin-mimetic co-administration data shows 3–5x GH peaks over either alone.

A typical stack runs 200 mcg ipa + 100 mcg CJC-1295 (no-DAC) subq, 1–3x daily. The pre-bed pin is almost always in there because overnight is when the natural GH pulse peaks, and stacking both with the endogenous pulse magnifies the effect.

CJC-1295 DAC stacked with ipa is a different protocol, weekly DAC pin + daily ipa, and it's less common because continuous GHRH signalling partially undermines ipa's pulsatile advantage.

What the Human Evidence Actually Shows

Ipa had pharma development through Novo Nordisk as a GI motility drug (not a GH therapy). Phase 2 trials for postoperative ileus showed good tolerability and some efficacy before the program was shelved, unrelated to safety (Beck et al., Aliment Pharmacol Ther, 2014). GH and IGF-1 elevation data from those trials exist but the drug was never developed for GH indications.

CJC-1295 DAC was developed by ConjuChem and ran Phase 2 trials in GH-deficient adults and HIV-associated lipodystrophy. Weekly dosing held IGF-1 elevation across the full inter-dose window at well-tolerated doses. Development stopped for commercial reasons, not safety.

Neither peptide is FDA-approved. Neither has published human data for the anti-aging or recomp uses they get marketed for in the research-peptide space.

Safety Profile

Both peptides have a generally favourable preclinical safety record. Common user-reported effects:

• —Injection site reactions (mild redness, tenderness), common with any subq pin
• —Transient headaches, more common with CJC-1295, usually resolve in the first week
• —Water retention / facial puffiness, scales with GH/IGF-1 elevation, more pronounced at higher doses or with DAC
• —Numb hands / tingling, classic GH side effect, usually dose-dependent
• —BG creep / elevated fasting insulin, GH transiently bumps insulin resistance; matters at high doses or in insulin-sensitive people

Both are banned by WADA. Neither is FDA-approved. Neither has been formally studied in pregnancy, lactation, or pediatric populations.

Choosing Between (or Combining) Them

• —Single-compound starting point: ipa alone at 200–300 mcg pre-bed for 4 weeks to establish baseline tolerability and effect.
• —Full mechanism stack (most common): ipa 200 mcg + CJC-1295 no-DAC 100 mcg subq, 1–2x daily, 8–12 week cycles. This is the recomp / lean gains workhorse.
• —Weekly compliance preference: CJC-1295 DAC at 1–2 mg weekly, with or without daily ipa.
• —Minimise cortisol impact: ipa beats GHRP-2 or GHRP-6 (also ghrelin-mimetics, but less selective).

The ipa + CJC-1295 stack guide covers full protocol detail. For individual profile data, see the ipamorelin research profile and the CJC-1295 entry in the library.

Related Reading

• —Where to buy ipamorelin
• —Ipamorelin + CJC-1295 stack guide

Frequently Asked Questions

Is CJC-1295 better than ipamorelin alone?

They're not directly comparable, they hit different receptors. CJC-1295 (either form) alone gives you a GHRH-pathway GH pulse. Ipa alone gives you a ghrelin-pathway GH pulse. Neither is "better"; they're complementary, which is exactly why almost every protocol runs both.

What's the difference between CJC-1295 DAC and Mod GRF 1-29?

Mod GRF 1-29 is the same peptide as CJC-1295 without the drug-affinity-complex (albumin-binding) group. ~30-minute half-life vs DAC's 6–8 days. For daily pulsatile dosing with ipa, you want no-DAC / Mod GRF. DAC is for weekly sustained signalling.

Do you have to stack them or can you run each alone?

You can run either alone. Ipa solo is a reasonable starting protocol. CJC-1295 alone is rare in practice because the mechanistic case for adding ipa is strong, and the side effect profile of the combo isn't meaningfully worse than mono.

When is CJC-1295 DAC preferred over no-DAC?

When weekly pin compliance matters more than preserved pulsatility, for example clinical research where dosing frequency is a trial-design constraint, or long protocols where daily injection adherence would slip. For most user protocols aimed at maxing GH pulse without desensitisation, no-DAC wins.

Do these peptides raise cortisol?

No. That was the specific design goal for ipa and it's what separates it from earlier ghrelin-mimetics (GHRP-6, GHRP-2). CJC-1295 is a GHRH analog and doesn't touch the adrenal axis at all.

Bottom Line

Ipa and CJC-1295 hit different receptors and their effects add together mechanically, that's why almost no serious protocol runs one without the other. The real choice is CJC-1295 DAC vs no-DAC, which is a pulsatility vs convenience call, not a mechanism call. If you're new to either, start with ipa alone for a short cycle to dial in tolerability; add no-DAC CJC-1295 next for the full combination.

This article is for research and informational purposes only. Ipamorelin and CJC-1295 are not FDA-approved for human clinical use. Banned by WADA in competitive sport.